183 related articles for article (PubMed ID: 38573347)
1. Phosphatidylserine externalization as immune checkpoint in cancer.
Kur IM; Weigert A
Pflugers Arch; 2024 Apr; ():. PubMed ID: 38573347
[TBL] [Abstract][Full Text] [Related]
2. Targeting phosphatidylserine for Cancer therapy: prospects and challenges.
Chang W; Fa H; Xiao D; Wang J
Theranostics; 2020; 10(20):9214-9229. PubMed ID: 32802188
[TBL] [Abstract][Full Text] [Related]
3. Biological Function and Immunotherapy Utilizing Phosphatidylserine-based Nanoparticles.
Glassman FY; Dingman R; Yau HC; Balu-Iyer SV
Immunol Invest; 2020 Oct; 49(7):858-874. PubMed ID: 32204629
[TBL] [Abstract][Full Text] [Related]
4. Lipid antioxidant, etoposide, inhibits phosphatidylserine externalization and macrophage clearance of apoptotic cells by preventing phosphatidylserine oxidation.
Tyurina YY; Serinkan FB; Tyurin VA; Kini V; Yalowich JC; Schroit AJ; Fadeel B; Kagan VE
J Biol Chem; 2004 Feb; 279(7):6056-64. PubMed ID: 14630936
[TBL] [Abstract][Full Text] [Related]
5. Blocking antibody-mediated phosphatidylserine enhances cancer immunotherapy.
Zhang J; Dai Z; Yan C; Wang D; Tang D
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3639-3651. PubMed ID: 34499223
[TBL] [Abstract][Full Text] [Related]
6. Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer.
Belzile O; Huang X; Gong J; Carlson J; Schroit AJ; Brekken RA; Freimark BD
Immunotargets Ther; 2018; 7():1-14. PubMed ID: 29417044
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylserine-Exposing Annexin A1-Positive Extracellular Vesicles: Potential Cancer Biomarkers.
Perez GI; Bernard MP; Vocelle D; Zarea AA; Saleh NA; Gagea MA; Schneider D; Bauzon M; Hermiston T; Kanada M
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992223
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?
Modena A; Ciccarese C; Iacovelli R; Brunelli M; Montironi R; Fiorentino M; Tortora G; Massari F
Oncol Rev; 2016 Apr; 10(1):293. PubMed ID: 27471580
[TBL] [Abstract][Full Text] [Related]
10. Immune-regulating bimetallic metal-organic framework nanoparticles designed for cancer immunotherapy.
Dai Z; Wang Q; Tang J; Wu M; Li H; Yang Y; Zhen X; Yu C
Biomaterials; 2022 Jan; 280():121261. PubMed ID: 34815099
[TBL] [Abstract][Full Text] [Related]
11. Exosome nanovesicles as potential biomarkers and immune checkpoint signaling modulators in lung cancer microenvironment: recent advances and emerging concepts.
Khan NA; Asim M; Biswas KH; Alansari AN; Saman H; Sarwar MZ; Osmonaliev K; Uddin S
J Exp Clin Cancer Res; 2023 Aug; 42(1):221. PubMed ID: 37641132
[TBL] [Abstract][Full Text] [Related]
12. Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.
Xu S; Wang C; Yang L; Wu J; Li M; Xiao P; Xu Z; Xu Y; Wang K
Front Immunol; 2023; 14():1199631. PubMed ID: 37313405
[TBL] [Abstract][Full Text] [Related]
13. Engagement of phospholipid scramblase 1 in activated cells: implication for phosphatidylserine externalization and exocytosis.
Smrz D; Lebduska P; Dráberová L; Korb J; Dráber P
J Biol Chem; 2008 Apr; 283(16):10904-18. PubMed ID: 18281686
[TBL] [Abstract][Full Text] [Related]
14. TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy.
Dayoub AS; Brekken RA
Cell Commun Signal; 2020 Feb; 18(1):29. PubMed ID: 32087708
[TBL] [Abstract][Full Text] [Related]
15. Reverting Immune Suppression to Enhance Cancer Immunotherapy.
Guerrouahen BS; Maccalli C; Cugno C; Rutella S; Akporiaye ET
Front Oncol; 2019; 9():1554. PubMed ID: 32039024
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials.
Yadav D; Kwak M; Chauhan PS; Puranik N; Lee PCW; Jin JO
Semin Cancer Biol; 2022 Nov; 86(Pt 2):909-922. PubMed ID: 35181474
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
18. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
19. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
Lazăr DC; Avram MF; Romoșan I; Cornianu M; Tăban S; Goldiș A
World J Gastroenterol; 2018 Aug; 24(32):3583-3616. PubMed ID: 30166856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
